USPTO serial 97363780
KOLMAR
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jun 4, 2024
- Examiner
- BUTTON, JENNIFER JO
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with KOLMAR?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
SEJONG-SI, KR
KOLMAR KOREA HOLDINGS CO., LTD.
Sejong-si, KR
KOLMAR KOREA HOLDINGS CO., LTD.
Sejong-si, KR
KOLMAR KOREA HOLDINGS CO., LTD.
Sejong-si, KR
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
David Youngjoon Jung
David Youngjoon Jung KAIROS Law Firm, PLLC2001 L Street N.W. Suite 500Washington, DC 20036United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Nutraceuticals for use as a dietary supplement; nutraceutical preparations for therapeutic or medical purposes, namely, nutraceutical preparations for the treatment of immune system related diseases and disorders, infectious diseases, metabolic diseases, kidney diseases, liver diseases, gastrointestinal diseases, inflammatory diseases, cancer and oncologic disorders, skin diseases and disorders, cardiovascular diseases, respiratory diseases, allergic diseases, neurological disorders and conditions, psychiatric disorders; dietary supplements; probiotic bacterial formulations for medical use; nutraceutical preparations mainly based on lactic acid bacteria; probiotic preparations for medical use; dietary supplements for humans; lacteal flour for babies; household deodorants; Medicines for human purposes, namely, for the treatment and relief of inflammation and inflammatory diseases and disorders; Medicines for human purposes, namely, antioxidants; Medicines for human purposes, namely, preparations for the treatment of allergies, hay fever, motion sickness, dermatologic use, namely, the treatment of dermatitis, skin pigmentation diseases, treatment of cold sores, treatment and prevention of dry skin, eczema, psoriasis, acne, for the treatment of atopic skin, the treatment of sunburn, irritated skin, cracking, cracks, insect bites, minor wounds, rashes, warts, for the treatment of diseases and symptoms within the central nervous system, namely, anxiety, spasms, sleep disorders, nervousness, irritability, nerves, apprehensiveness, emotional palpitations, for the treatment of disorders and conditions involving the joints, muscles, tendons and ligaments, for the treatment of joint pain, muscle, muscle fatigue, cramps, fatigue states, for the treatment of toothache, for the treatment of infections of the mouth, for the treatment of bruises, bumps, aches, pain, fever, headaches, vitamin-based nutritional supplements and mineral supplements; Medicines for human purposes, namely, bacterial and bacteriological preparations for medical purposes; disposable baby diapers; vitamin preparations; mineral food supplements; cultures of microorganisms for medical use; Dietetic substances, namely, infant formula and food for babies adapted for medical use; Dietetic substances, namely, beverages and food adapted for medical use; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparation for skin care; Pharmaceutical preparations for treatment of hepatitis; Pharmaceutical preparations for the treatment of musculoskeletal disorders; Pharmaceutical preparations for the treatment of diseases of the endocrine system; Pharmaceutical preparations for urogenital organs; Cardiovascular pharmaceutical preparations; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations, namely, medicated toiletry preparations, medicated soaps, skin lotions for pharmaceutical purposes; Pharmaceutical preparations for respiratory organs; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceuticals, namely, antioxidants; Pharmaceutical agents affecting digestive organs; Pharmaceuticals, namely, antibiotics and anti-infectives for the treatment and prevention of infectious diseases and obesity, fat and cholesterol control, blood sugar control and strengthening of immune system; Pharmaceuticals preparations and substances for the treatment of pain, inflammation, damaged skin and tissues and wounds; Pharmaceuticals preparations and substances for use in treating dermatitis, eczema, psoriasis, ulcerating wounds, skin diseases, skin conditions and lesions; Pharmaceutical skin lotions; probiotic supplements; preparations of microorganisms for medical or veterinary use; nutritional supplements | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by KOLMAR HOLDINGS CO., LTD.
- Other trademarks owned by KOLMAR KOREA HOLDINGS CO., LTD.
- Other trademarks owned by KOLMAR KOREA HOLDINGS CO., LTD.
- Other trademarks owned by KOLMAR KOREA HOLDINGS CO., LTD.
- Other trademarks in Class 005
- Similar marks named KOLMAR
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 26, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 26, 2026 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Mar 26, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 26, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 17, 2025 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Jun 17, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 17, 2025 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Jun 17, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 17, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 17, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jun 17, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jun 6, 2024 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Jun 4, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jun 4, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 19, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 19, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 28, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 28, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 16, 2024 | OTHE | CASE RETURNED TO EXAMINATION | — |
| Jan 16, 2024 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Dec 7, 2023 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Dec 7, 2023 | PCBG | PETITION TO DIRECTOR - CHANGE BASIS - GRANTED | — |
| Dec 7, 2023 | APET | ASSIGNED TO PETITION STAFF | — |
| Nov 10, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 8, 2023 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Nov 8, 2023 | EXT1 | SOU EXTENSION 1 FILED | — |
| Nov 8, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 8, 2023 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| Nov 8, 2023 | TPAD | TEAS PETITION TO AMEND BASIS RECEIVED | — |
| May 9, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Mar 14, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 14, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 22, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 7, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 31, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 20, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 18, 2022 | NWAP | NEW APPLICATION ENTERED | — |